View Older Stories View More Recent Stories

Nov 6, 2020 02:16PM Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Oct 30, 2020 08:00AM Ligand Reports Third Quarter 2020 Financial Results
Oct 23, 2020 08:34AM Ligand Pharma (LGND) Says its Captisol Technology Plays Key Role in Manufacture of Gilead's COVID-19 Treatment Veklury
Oct 23, 2020 08:30AM Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
Oct 20, 2020 02:10PM Ligand Pharma (LGND) Provides Highlights from Today’s Investor Day Event
Oct 20, 2020 02:05PM Ligand Provides Highlights from Today’s Investor Day Event
Oct 19, 2020 04:02PM Ligand’s Third Quarter Financial Results to be Reported October 30th
Oct 12, 2020 09:00AM Ligand Pharma (LGND) to Divest Vernalis Research Operations
Oct 12, 2020 09:00AM Ligand to Divest Vernalis Research Operations
Oct 2, 2020 08:00AM Ligand to Host Virtual Investor Day on October 20th
Oct 1, 2020 08:26AM Ligand (LGND) Completes Acquisition of Pfenex Inc. (PFNX)
Oct 1, 2020 08:24AM Ligand Completes Acquisition of Pfenex Inc.
Sep 30, 2020 08:04AM Ligand Pharma (LGND) Announces Expiration of Tender Offer for Shares of Pfenex (PFNX), Expects Merger to Close on October 1
Sep 30, 2020 08:00AM Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
Sep 23, 2020 08:04AM Ligand Pharma (LGND) Says Captisol Business is Positioned for Major Growth, Forecasts 2021 Captisol Material Sales of $200 Million
Sep 23, 2020 08:00AM Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Sep 10, 2020 08:00AM Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
Sep 1, 2020 04:02PM Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Aug 31, 2020 09:04AM Ligand Pharma (LGND) Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc. (PFNX)
Aug 31, 2020 09:00AM Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.
Aug 25, 2020 04:15PM Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
Aug 24, 2020 08:44AM Ligand (LGND) Announces Amgen's (AMGN) KYPROLIS Approved by FDA as Combination Regimen with DARZALEX and Dexamethasone in for Patients with R/R Multiple Myeloma
Aug 24, 2020 08:30AM Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple
Aug 10, 2020 05:37PM Ligand Pharma (LGND) to Acquire Pfenex (PFNX) for $12 Per Share in Cash Plus CVR
Aug 10, 2020 05:36PM Ligand to Acquire Pfenex Inc.
Aug 7, 2020 08:38AM Ligand Pharma (LGND) Announces CStone Reported OmniAb-derived CS1001 Phase 3 Trial Met Primary Endpoint as First-Line Treatment in Stage IV NSCLC and Announces Plans to Submit NDA
Aug 7, 2020 08:30AM CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces P
Aug 3, 2020 07:30AM Ligand Reports Second Quarter 2020 Financial Results
Jul 16, 2020 04:28PM Ligand’s Second Quarter Financial Results to be Reported August 3rd
Jun 15, 2020 08:33AM Ligand Pharma (LGND) Reports Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets
Jun 15, 2020 08:30AM Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets
Jun 1, 2020 04:53PM Ligand CEO Issues Letter to Captisol Customers
May 29, 2020 08:05AM Ligand Pharma (LGND) Announces Icagen's Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
May 29, 2020 08:00AM Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
May 28, 2020 04:23PM Ligand Pharma (LGND) Earns $3 Million Milestone Payment from Palvella Therapeutics
May 28, 2020 04:22PM Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
May 6, 2020 04:01PM Ligand Reports First Quarter 2020 Financial Results
Apr 22, 2020 08:30AM Ligand’s First Quarter Financial Results to be Reported May 6th
Apr 6, 2020 07:00AM Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
Apr 2, 2020 04:02PM Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
Mar 10, 2020 08:00AM Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com
Mar 2, 2020 08:00AM Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
Feb 27, 2020 08:03AM Ligand Pharma (LGND) Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
Feb 27, 2020 08:00AM Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
Feb 11, 2020 04:37PM Ligand Pharma (LGND) to Acquire Core Assets from Icagen
Feb 11, 2020 04:14PM Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen
Feb 6, 2020 04:01PM Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 3, 2020 08:30AM Ligand's Technologies Support and Enable Potential Coronavirus Treatments
Jan 21, 2020 08:00AM Lemelson Capital Management Reports FYE 2019 Results for The Amvona Fund, LP
Jan 13, 2020 04:02PM Ligand Pharma (LGND) Enters into OmniAb Platform License Agreement with Pandion Therapeutics
View More Recent Stories View Older Stories